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We aimed to identify the fatal pulmonary hemorrhage- (FPH-) related risk factors in stage 3B/C squamous-cell lung carcinoma
(SqCLC) patients treated with definitive concurrent chemoradiotherapy (C-CRT). Medical records of 505 stage 3B/C SqCLC
patients who underwent 66Gy radiotherapy plus 1-3 cycles of concurrent chemotherapy with available pretreatment thoracic
computerized tomography scans were retrospectively analyzed. Primary end-point was the identification of FPH-related risk
factors. Examined factors included the basal patient and tumor characteristics with specific emphasis on the tumor cavitation
(TC) status, tumor size (TS) and cavitation size (CS), tumor volume and cavitation volume (TV and CV), relative cavitation size
(RCS = CS/TS), and relative cavitation volume (RCV=CV/TV). FPH emerged in 13 (2.6%) patients, with 12 (92.3%) of them being
diagnosed ≤12 months of C-CRT. All FPHs were diagnosed in patients with TC (N=60): group-specific FPH incidence: 21.6%. TC
(P<0.001) was the unique independent factor associated with higher FPH risk in multivariate analysis. Further analysis limited
to TC patients exhibited the RCV>0.14 (37.5% versus 11.1% for RCV≤0.14; P<0.001), major RCS group [31.0% versus 19.0% for
minor versus 0% for minimum RCS; P=0.008), and baseline hemoptysis (26.3% versus 13.6% for no hemoptysis; P=0.009) as the
independent risk factors for higher FPH incidence. FPH was an infrequent (2.6%) complication of C-CRT in stage 3B/C SqCLC
patients, but its incidence increased to 37.5% in patients presenting with TC and RCV>0.14. Diagnosis of >90% FPHs ≤12 months
of C-CRT stresses the importance of close and careful follow-up of high-risk patients after C-CRT for multidisciplinary discussion
of possible invasive preventive measures.
1. Introduction
Survival advantage exhibited by phase III randomized con-
trolled trials set the concurrent chemoradiotherapy (C-CRT)
as the standard treatment decision for inoperable stage III
non-small-cell lung cancer (NSCLC) patients [1, 2]. How-
ever, the established superiority of C-CRT over RT alone
and sequential- or split-course CRT modalities undoubtedly
came at the cost of notably increased normal tissue com-
plication rates, particularly the RT-induced esophagitis and
pneumonitis [3, 4].
Another serious but underestimated complication of RT
or C-CRT in NSCLC is fatal pulmonary hemorrhage (FPH)
with an incidence rate of 1.5-3.5% for all patients [5, 6].
However, this rate may increase up to 36% in cavitating
squamous-cell lung cancers (SqCLC) [5, 6]. FPH has likewise
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been documented in NSCLCs undergoing endobronchial
brachytherapy [7, 8], stereotactic body RT [9, 10], and
antiangiogenic therapies [11, 12]. Interestingly, despite its life-
threatening nature, to date, FPH-related risk factors following
CRT have been studied in only a single study of 583 stage 2-3
NSCLC patients by Ito et al. [6]. The overall FPH incidence
was 2.1% in this study, with SqCLC histology and tumor
cavitation (TC) size being the significant associates of FPH.
However, rendering thorough interpretation of the outcomes
difficult, the authors provided no information about the
total and per fraction doses of RT, exact type of CRT, and
chemotherapy details, either of which may significantly alter
the FPH rates. Moreover, decreasing the statistical power,
the SqCLC cohort that has the highest risk for TC and
FPH incidences constituted only 34.7% of the entire study
population.
With reference to the absence of large exclusive SqCLC
series, present retrospective study was conducted to further
investigate the FPH-related risk factors following definitive
C-CRT in a large cohort of consecutively treated stage 3B/C
SqCLC patients.
2. Patients and Methods
2.1. Study Population. An institutional database search was
performed to identify all patients who underwent C-CRT
between January 2007 and December 2014 for stages 3B/C
SqCLC according to American Joint Committee on Cancer
(8th ed.) and met the following criteria: age of 18-80 years;
available diagnostic chest computerized tomography (CT);
18F-fluorodeoxyglucose positron emission CT (PET-CT);
Eastern Cooperative Oncology Group (ECOG) performance
of 0-1; available pre-C-CRTbrainmagnetic resonance images,
treatment charts, and hospital computerized datasets of
RT and chemotherapy; at least 1 concurrent chemotherapy
cycle administered; and no prior RT/chemotherapy histo-
ries. Patients presented with malignant pleural/pericardial
effusion, inadequate pulmonary, cardiac, renal, or hep-
atic functions, and blood count/chemistry and those who
received antiangiogenic therapies for relapses after C-CRT
were excluded. The study was approved by the institutional
review board before collection of any patient information.
2.2. ConcurrentChemoradiotherapy. All patientswere treated
with 3-dimensional conformal (3D-CRT) or intensity-
modulated RT (IMRT). Target volume definition and
treatment technique for RT and organ at risk dose restrictions
utilized here were as previously described by Topkan et al.
elsewhere [13]. Briefly, all patients received a total dose of
66Gy RT in 33 fractions and 1 to 3 cycles of Cisplatin plus one
of Vinorelbine, Docetaxel/Paclitaxel (Taxanes), or Etoposide.
Standard supportive and symptomatic care measures were
administered as indicated.
2.3. Fatal Pulmonary Hemorrhage Definition. FPH was
defined as pulmonary hemorrhage that leads to inevitable
fatality within 24 hours of its onset despite any type of
intervention, excluding the causes related with proved tumor
progression, infection, or trauma.
2.4. Assessment of Tumor Cavitation. TC was defined as
presence of an air-containing cavity within the primary
tumor mass on the pretreatment chest CT scans, which has
been proposed to be a significant risk factor for FPH after C-
CRT [6].Therefore, the baseline chest CT scans of all patients
were assessed by an experienced radiation oncologist on
cavitating lung tumors (E.T) in order to determine the pres-
ence/absence of TC and delineate its borders on coregistered
diagnostic and planning CT scans. If TC was multiloculated
in the TV, all separate TC volumes were combined and
considered as one CV. The TC presence status, largest sizes
and volumes of the primary tumor and TC, and their relative
ratios were evaluated as potentially relevant baseline tumor
characteristics which may interact with FPH diagnosis.
2.5. Statistics. We primarily aimed to identify the incidence
rate of FPH and related risk factors after definitive C-CRT in
stage 3B/C SqCLC patients. Evaluable risk factors included
the age, gender, ECOG performance, smoking history and
duration, tumor stage and location, baseline hemoptysis,>5%
weight loss status at past 6 months, baseline anemia and TC
status, largest sizes and volumes of the primary tumor and
TC and their relative ratios, RT technique, and concurrent
chemotherapy protocol and cycles.
As the largest diameters of the TC and primary tumor
may not always reflect the respective true volumes because
of significant variations in their shapes and remaining two
dimensions, we created a novel volumetric methodology to
classify TCs, whereas Ito’s classification was utilized only for
comparative analyses [6]. Accordingly, we delineated and
measured the tumor (TV) and TC (TCV) volumes separately
for each patient by utilizing the diagnostic chest CT scans and
defined the relative cavitation volume (RCV) as the TCV/TV
ratio for further analyses. Likewise, the largest primary tumor
(TS) and TC (TCS) sizes were measured and the relative
cavitation size (RCS) was calculated for each patient as the
TCS/TS ratio for Ito’s TC classification: minimum: RCS<0.25,
minor: RCS≥0.25 but <0.50, and major: RCS≥0.50.
Mean, median, and ranges were used for the quantitative
variables, whereas frequency distributions were used to
describe the categorical variables. Frequency distributions
were compared by using Chi-square test, Student’s t-test,
Pearson’s exact test, or Spearman’s correlations. Receiver
operating characteristic (ROC) curve analysis was utilized
to identify potential cut-off values for continuous variables,
such as the RCS and RCV, which may stratify patients into
distinctive FPH risks groups. Fisher’s exact test and logistic
regression test were used for univariate and multivariate
analyses, respectively. Multivariate analyses included only
the variables exhibiting significance in univariate analyses. A
two-sided P-value <0.05 was considered significant.
3. Results
Present database search identified a total of 505 stage IIIB/C
SqCLC patients who met the protocol inclusion criteria.
Baseline demographics and treatment characteristics were as
depicted in Table 1. Of all patients, 16.2% were geriatric (>70
years). Smoking history was present in 93.9% of patients with
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Table 1: Baseline demographics and treatment characteristics.
Variable All Patients(n=505)
Median age, y (range) 65.1 (32-79)
Age group, n (%)
≤70 years 423 (83.8)
>70 years 82 (16.2)
Gender, n (%)
Male 352 (69.7)
Female 153 (30.3)
ECOG performance, n (%)
0 205 (40.6)
1 300 (59.4)
Smoking history, n (%)
Absent 31 (6.1)
Present 474 (93.9)
Median smoking duration,
pack/y 28 (0-132)
Weight loss, n (%)
≤5% 395 (78.2)
>5% 110 (21.8)
aAnemia, n (%)
Absent 325 (64.4)
Present 180 (35.6)
Hemoptysis, n (%)
Absent 354 (70.1)
Present 151(29.9)
Stage, n (%)
3B 275 (54.5)
3C 230 (45.5)
Tumor location
Central 224 (44.4)
Peripheral 281 (55.6)
Median largest tumor size,
cm (range) 5.1 (2.4-9.8)
Median tumor volume, cm3
(range) 50.8 (19.3-149.4)
Chemotherapy, n (%)
CV 251 (49.8)
CT 226 (44.7)
CE 28 (5.5)
Chemotherapy cycles, n
(%)
1 35 (6.9)
2 91 (18.0)
3 379 (75.1)
RT technique, n (%)
3D-CRT 286 (56.7)
IMRT 219 (43.3)
Table 1: Continued.
Variable All Patients(n=505)
Tumor cavitation, n (%)
Absent 445 (88.1)
Present 60 (11.9)
aHemoglobin: <130 g/dL for men and <120 g/dL for women.
ECOG: Eastern Cooperative Oncology Group; CV: Cisplatin + Vinorelbine;
CT: Cisplatin + Taxane; CE: Cisplatin + Etoposide; 3D-CRT: 3-dimensional
conformal radiotherapy; IMRT: intensity-modulated radiotherapy.
a median smoking duration of 28 pack/years (range: 0-132).
The Cisplatin-Vinorelbine doublet was the most commonly
utilized chemotherapy (49.8%), and 75.1% of patients were
able to receive all 3 prescribed chemotherapy courses during
the RT. Baseline hemoptysis, WL>5% at past 6 months, and
anemia were evident in 29.9%, 21.8%, and 35.6% of cases,
respectively. TC was diagnosed in 60 (11.8%) patients.
At a median follow-up time of 28.3 months (range: 24.1-
32.5), FPH was diagnosed in 17 (3.4%) patients. However, 13
(2.6%) of them were judged to be true FPHs, as progressive
primary tumors invading the major vessels were demonstra-
ble in remaining 4 cases. All FPHs were diagnosed in 60
individuals with TC, accounting for an overall FPH incidence
rate of 21.6% in this group. Median time fromC-CRT to FPH
diagnosis was 4.4 months (range: 2.3-13.1), with 8 (61.5%), 4
(30.8%), and 1 (7.7%) cases being diagnosed within 6, 6 to 12,
and >12 months of C-CRT, respectively.
Results of univariate analyses discovered the central
tumor location (r2=0.23; P=0.026), basal hemoptysis
(r2=0.38; P=0.032), and TC (r2=0.91; P<0.001) as the
significant correlates of higher FPH risk in the entire study
population (Table 2). Outcomes of multivariate analyses
limited to these covariates discovered the TC (P<0.001)
as the unique factor to retain its independent significant
association with FPH risk (Table 2).
In order to identify specific group(s) with the highest
FPH risk, we restricted our further analyses to patients
presenting with TC (N=60), as all FPHs were diagnosed
in this group (Table 3). Before univariate analysis, we first
searched for the availability of significant cut-off(s) for TS
and TCS, TV, TCV, RCS, and RCV in TC patients which
may stratify them into distinctive FPH risk groups. For this
purpose, we performed ROC curve analysis, results of which
revealed only a significant cut-off value for RCV at 0.14 point
(area under the curve=87.3%; sensitivity: 80.7%; specificity:
77.8%)with no further identifiable cut-offs for other variables
(Figure 1). Therefore, the median values were utilized for
these variables in further analyses. Then, RCSs were classified
as minimum (N=10; 16.7%), minor (N=21; 35.0%), and major
(N=29; 48.3%) according to Ito’s methodology [6].Themajor
RCS group appeared to have the highest FPH risk (31.0%)
followed by the minor (19%) and minimum (0%) RCS
groups (P= 0.008). Lastly, we dichotomized the TC patients
into two groups according to their RCVs: Group 1 (N=36):
RCV≤0.14 and Group 2 (N=24): RCV>0.14. Comparative
analysis demonstrated that the risk of FPH was significantly
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Table 3: Uni- and multivariate correlates of fatal pulmonary hemorrhage in patients with tumor cavitation.
Variable Patients(N=60)
FPH
(N=13)
Univariate
P-value
Multivariate
P-value
aMedian TS, n (%)
<5.1 cm 27 (45.0) 6 (22.2) 0.68 -
≥5.1 cm 33 (54.0) 7 (21.2)
aMedian TV, n (%)
≤58.9 cm3 26 (43.3) 5 (19.2) 0.57 -
>58.9 cm3 34 (56.7) 8 (23.4)
aMedian CS, n (%)
< 2.6 cm 28 (46.7) 6 (21.4) 0.86 -
≥ 2.6 cm 32 (53.3) 7 (21.9)
aMedian CV, n (%)
< 22.3 cm3 27 (45.0) 5 (18.5) 0.23 -
≥ 22.3 cm3 33 (55.0) 8 (242
aMedian RCS, n (%)
< 0.46 31 (51.7) 5 (16.1) 0.09 -
≥ 0.46 29 (48.3) 8 (27.6)
Ito’s RCS group, n (%)
Minimum (≤0.25) 10 (16.7) 0 (0) 0.006 0.008
Minor (≥0.25 but <0.50) 21 (35.0) 4 (19.0)
Major (≥0.5) 29 (48.3) 9 (31.0)
RCV group, n (%)
≤0.14 36 (55.0) 4 (11.1) <0.001 <0.001
>0.14 24 (45.0) 9 (37.5)
Hemoptysis, n (%)
Absent 22 (36.7) 3 (13.6) 0.007 0.009
Present 38 (63.3) 10 (26.3)
bMedian values were used, as receiver operating characteristic analysis did not reveal significant cut-off.
FPH: fatal pulmonary hemorrhage; TS: tumor size; TV: tumor volume; CS: cavitation size; CV: cavitation volume; RCS: relative cavitation size (largest tumor
diameter/largest cavitation diameter); RCV: relative cavitation volume (cavitation volume/tumor volume).
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Figure 1: Outcomes of receiver operating characteristic curve
analysis for the association between the relative cavitation volume
and fatal pulmonary hemorrhage incidence risk.
higher in Group 2 compared to Group 1 (37.5% versus
11.1%; P<0.001). Among other factors, only the presentation
with baseline hemoptysis appeared to be significantly asso-
ciated with higher FPH risk (26.3% versus 13.6%; P=0.007)
(Table 3). Results of multivariate analysis limited to Ito’s
groups, RCV groups, and hemoptysis status revealed that
each factor retained its independent significant association
with FPH risk, with RCV grouping being the strongest
stratification factor according to the related multivariate P-
values (Table 3).
4. Discussion
Results of our present large retrospective study in 505 stage
3B/C SqCLC demonstrated that the overall FPH risk after
definitive C-CRT was 2.6%. TC was found to be the unique
independent factor to predict FPH risk in the whole study
population as all FPHs (N=13) were diagnosed in TC patients
(N=60) with an increased FPH risk of 21.6% in this cohort.
Resultant limitation of the analyses to TC cohort additionally
discovered the presenting hemoptysis, Ito’s major TC class,
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and RCV>0.14 as the significant predictors of higher FPH risk
in this particular group, with RCV>0.14 being the strongest
factor among them.
The primary goal of our present research was to deter-
mine the key factors that may prove useful in identification
of patients with the highest FPH risk after definitive C-CRT.
Either of the rapid tumor regression, bronchial and/or vessel
wall necrosis, or vascular endothelial abnormalities after
thoracic RT/C-CRT may cause bronchovascular fistula. By
extension, it is rational to postulate RT and to a larger extent
C-CRT as potential causes of FPH with regard to the proven
roles of RT-induced bronchovascular fistula and vascular
abnormalities in the FPH pathogenesis [14–16]. However,
excluding the single study by Ito et al. [6], all previous studies
focused on the risk factors in NSCLC patients undergoing
antiangiogenic therapies, such as bevacizumab, sunitinib,
and sorafenib [17–19], and demonstrated a clear association
between these agents and increased FPH risk mainly in non-
SqCLCs. Despite the fact that FPH emerges in up to 50%
NSCLC patients treated with endobronchial brachytherapy
[7, 8, 16], investigations that concentrated on its incidence and
related risk factors after RT/C-CRTare scarce, with a reported
1.5-3.5% incidence range [5–7, 20]. However, this rate may
increase up to 36% in cavitating SqCLCs [5, 6]. Hence, the
accessible basic and clinical evidencemotivated us to conduct
this present study to identify the candidates who might
require treatment customization in follow-up by further
addressing the incidence and risk factors of FPH particularly
in exclusive SqCLC patients who underwent standard C-CRT
for stage 3B/C disease with no antiangiogenic therapies at any
phases of their treatment course.
Thefirst important finding of our studywas the exhibition
of a very strong and independent association between the
TC presence and FPH risk (N=13) after C-CRT, such that
although overall incidence of FPH was 2.6% in the whole
study population, this value increased to 21.6% in TC cohort
with no FPHdiagnosis (0%) in the non-TC cohort (P<0.001).
The exact mechanism of increased FPH rates in TC cohort
has not been clarified yet, but vascular invasion by the tumor
cells and related intratumoral ischemia have previously been
reported to be common features of cavitating SqCLCs [21],
which cause FPHbydisruption of the abnormal tumor vessels
via secretion of several transcription factors and angiogenic
cytokines, such as the hypoxia-inducible transcription factors
and vascular endothelial growth factors [22]. Whatever the
exact cause of FPH is, the 2.6% FPH incidence reported
here accords well and confirms the respective 2.3% and 2.1%
incidence rates previously reported in Phermanbucq’s [20]
and Ito’s [6] CRT studies. Moreover, our present findings
that suggest the TC as the unique factor to be associated
with increased FPH risk do not only lend support for Ito’s
observation of all 3 FPHs in their SqCLC subgroup with TCs
but also clearly set the SqCLC plus TC combination as the
major risk factor for FPH emergence after definitive C-CRT
as well.
Because all 13 FPHs were diagnosed in 60 patients
with TC, our secondary analyses limited to TC population
revealed 3 additional important findings in this particular
group: (1) hemoptysis as a significant associate of FPH, (2)
confirmation of the utility of Ito’s 3 laddered RCS-based FPH
risk stratification methodologies, and (3) demonstration of
large RCV>0.14 as a novel independent volumetric predictor
of higher FPH risk. To begin with, compared with the
former study by Ito et al. [6] which could not reveal a
notable interaction between the baseline hemoptysis and
FPH risk, the significant association between the baseline
hemoptysis and higher FPH risk demonstrated here is a new
finding. Although it is difficult to assign this discrepancy
to solid reasons, the differences between the two statistical
methodologies may be explanatory. In Ito’s study, the authors
limited their analysis to the whole population which included
different histologies and stages, with no respect to their TC
status. In contrast, because the tumoral blood vessel erosion
is a common cause for hemoptysis and TC particularly in
the locally aggressive SqCLC [23], we further analyzed the
interaction between the baseline hemoptysis and TC status
in our exclusive stage 3B/C SqCLC patients presenting with
TC. Although further validation is needed, the present strong
association demonstrated in a statistically more powered
large SqCLC cohort suggests that the authors may have prob-
ably missed the chance for reaching a statistically significant
outcome on this particular issue.
Considering Ito’s RCS and our novel RCV grouping
systems, our results did not only lend support for Ito’s
system to some extent but additionally demonstrated that the
grouping of TC patients according to RCV cut-off of 0.14 was
the strongest predictor of higher FPH risk in this patients’
group (37.5% for RCV>0.14 versus 11.1% for RCV≤0.14;
P<0.001). Present methodology is notably different from the
one utilized by Ito et al. [6]. Revealed from the manuscript,
Ito’s team used arbitrary cut-offs at 0.25 and 0.50 points
rather thanusing those obtained frommore objective analytic
methods, such as the ROC curve analysis. In fact, because
we could not define a significant cut-off for RCS in the ROC
curve analysis, we believe that our confirmatory results for
RCS should still be interpreted with caution and readdressed
in further studies. Comparably, present 3-dimensional volu-
metric methodology and use of undoubtedly more objective
ROC curve analysis results appear to be more confiden-
tial than Ito’s arbitrarily stratified unidimensional metric
methodology. Because both the tumors and the TCs are
naturally 3-dimensional volumetric structures, utilization of
unidimensional largest diameters as the end-point measures
will usually carry the risks for over- or underestimation of the
outcomes, as this methodology does not care for the other
determinants of volumetric calculations, namely, the other
two dimensions and the shape of the volumes in interest. In
contrast, representing a replicable andmore reliable method-
ology, the volumetric measurements utilized in this present
study care for both of the shapes and all three dimensions of
the individual TV and TCV in a simultaneous manner.
The last essential result of the current study was the
diagnoses of the respective 8 (61.5%) and 12 (92.3%) of all 13
FPHs within 6 and 12 months of the C-CRT. Unfortunately,
rendering the comparisons between the two studies impos-
sible, Ito’s group did not provide any information about the
interval between the CRT and FPH diagnoses [6]. However,
Phernambucq et al. reported 2 FPHs at 1 month of C-CRT
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[20]. Dingemans et al. in phase I study of individualized,
isotoxic accelerated C-CRT reported 1 FPH at 4months of C-
CRT [24]. Likewise, Llandau et al. reported 3 FPHs at 1, 4.5,
and 14 months of C-CRT in their phase 1/2 trial of isotoxic
dose-escalated C-CRT [25]. Altogether, these results suggest
the FPH as an early event after C-CRT and recommend
the careful close follow-up of high-risk patients, at least
for the first 12 months of C-CRT. Such an approach may
prevent FPH-related deaths in appropriately selected high-
risk patients by means of timely use of preventive measures,
such as planned post-C-CRT surgery in resectable peripheral
tumors regardless of their nodal status or percutaneous
embolotherapy/bronchial artery embolization [26, 27].
The present study has drawbacks. First, common to
any single-institutional retrospective analysis, some unpre-
dictable biases may have affected our results. Second, despite
the overall large cohort size, diagnosis of all FPHs solely
in the TC group comprising only 60 patients limited our
ability to stratify these patients into further risk groups
by utilizing recursive partitioning analysis methodology
according to the accompanying significant predictors of FPH:
baseline hemoptysis and RCV status. However, despite these
limitations, this is the first study to identify the factors
associated with significantly increased FPH risk after a
relatively homogenous C-CRT protocol in a large cohort of
exclusive stage 3B/C SqCLC patients who never received
antiangiogenic therapy during any phase of treatment.
5. Conclusion
Results of this single institutional large cohort study clearly
demonstrated that the presence of pretreatment TC was the
unique independent predictor of relatively infrequent but
life-threatening FPH following definitive C-CRT in stage
3B/C SqCLC patients. Furthermore, the analysis restricted
to TC cohort additionally exhibited that RCV>0.14, with a
FPH incidence of 37.5%, was the most notable risk factor
for FPH emergence during the post-C-CRT period. Finally,
diagnosis of vast majority of all FPHs (92.3%) in the first 12
months of C-CRT is strongly suggestive of close and careful
follow-up of such patients against this fatal complication for
multidisciplinary discussion of possible invasive preventive
measures such as planned post-C-CRT surgery or percuta-
neous embolotherapy/bronchial artery embolization.
Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request.
Conflicts of Interest
The authors declare that there are no conflicts of interest.
Authors’ Contributions
Erkan Topkan and Ugur Selek contributed to conception and
design of the study andmanuscript writing. YurdayOzdemir,
Ali A. Besen, Huseyin Mertsoylu, Berna A. Yildirim, Alper
Findikcioglu, Ozgur Ozyilkan, and Berrin Pehlivan con-
tributed to collection and assembly of data. Erkan Topkan,
Yurday Ozdemir, Ozan C. Guler, Ali A. Besen, Huseyin
Mertsoylu, Alper Findikcioglu, Ozgur Ozyilkan, and Berrin
Pehlivan contributed to data analysis and interpretation. All
authors approved the final manuscript.
References
[1] K. Furuse, M. Fukuoka, M. Kawahara et al., “Phase III study of
concurrent versus sequential thoracic radiotherapy in combi-
nation withmitomycin, vindesine, and cisplatin in unresectable
stage III non-small-cell lung cancer,” Journal of Clinical Oncol-
ogy, vol. 17, no. 9, pp. 2692–2699, 1999.
[2] W. J. Curran Jr., R. Paulus, and C. J. Langer, “Sequential vs.
concurrent chemoradiation for stage III non-small cell lung
cancer: randomized phase III trial RTOG 9410,” Journal of the
National Cancer Institute, vol. 103, no. 19, pp. 1452–1460, 2011.
[3] A. Aupe´rin, C. Le Pe´choux, E. Rolland et al., “Meta-analysis
of concomitant versus sequential radiochemotherapy in locally
advanced non - small-cell lung cancer,” Journal of Clinical
Oncology, vol. 28, no. 13, pp. 2181–2190, 2010.
[4] D. Ball, J. Bishop, J. Smith et al., “A randomised phase III
study of accelerated or standard fraction radiotherapy with or
without concurrent carboplatin in inoperable non-small cell
lung cancer: Final report of an Australian multi-centre trial,”
Radiotherapy & Oncology, vol. 52, no. 2, pp. 129–136, 1999.
[5] R. J. Panos, L. F. Barr, T. J. Walsh, and H. J. Silverman, “Factors
associated with fatal hemoptysis in cancer patients,” CHEST,
vol. 94, no. 5, pp. 1008–1013, 1988.
[6] M. Ito, S. Niho, K. Nihei, K. Yoh, H. Ohmatsu, and Y. Ohe,
“Risk factors associated with fatal pulmonary hemorrhage
in locally advanced non-small cell lung cancer treated with
chemoradiotherapy,” BMC Cancer, vol. 12, 2012.
[7] C. Aygun, S. Weiner, A. Scariato, D. Spearman, and L. Stark,
“Treatment of non-small cell lung cancer with external beam
radiotherapy and high dose rate brachytherapy,” International
Journal of Radiation Oncology ∙ Biology ∙ Physics, vol. 23, no. 1,
pp. 127–132, 1992.
[8] R. M. Huber, R. Fischer, H. Hautmann, B. Po¨llinger, K.
Ha¨ußinger, and T. Wendt, “Does additional brachytherapy
improve the effect of external irradiation? A prospective, ran-
domized study in central lung tumors,” International Journal of
Radiation Oncology ∙ Biology ∙ Physics, vol. 38, no. 3, pp. 533–
540, 1997.
[9] F. Oskan, G. Becker, and M. Bleif, “Specific toxicity after
stereotactic body radiation therapy to the central chest: A
comprehensive review,” Strahlentherapie und Onkologie, vol.
193, no. 3, pp. 173–184, 2017.
[10] U. Ricardi, A. R. Filippi, A. Guarneri et al., “Dosimetric
predictors of radiation-induced lung injury in stereotactic body
radiation therapy,” Acta Oncologica, vol. 48, no. 4, pp. 571–577,
2009.
[11] A. B. Sandler, J. H. Schiller, R. Gray et al., “Retrospective evalua-
tion of the clinical and radiographic risk factors associatedwith
severe pulmonary hemorrhage in first-line advanced, unre-
sectable non-small-cell lung cancer treated with carboplatin
and paclitaxel plus bevacizumab,” Journal of Clinical Oncology,
vol. 27, no. 9, pp. 1405–1412, 2009.
[12] C. Sandomenico, R. Costanzo, and G. Carillio, “Bevacizumab
in NSCLC: development, current status, and issues,” Current
Medicinal Chemistry, vol. 19, no. 7, pp. 961–967, 2012.
Journal of Oncology 9
[13] E. Topkan, C. Parlak, and U. Selek, “Impact of weight change
during the course of concurrent chemoradiation therapy on
outcomes in stage IIIB non-small cell lung cancer patients:
Retrospective analysis of 425 patients,” International Journal of
Radiation Oncology ∙ Biology ∙ Physics, vol. 87, no. 4, pp. 697–
704, 2013.
[14] R. D. Isaacs, W. J. Wattie, A. U. Wells, H. H. Rea, and T. R.
Bai, “Massive haemoptysis as a late consequence of pulmonary
irradiation.,”Thorax, vol. 42, no. 1, pp. 77-78, 1987.
[15] T. L. Phillips, M. D.Wharam, and L.W.Margolis, “Modification
of radiation injury to normal tissues by chemotherapeutic
agents,” Cancer, vol. 35, no. 6, pp. 1678–1684, 1975.
[16] J. A. Langendijk, M. K. T. Tjwa, J. M. A. de Jong, G. P. M.
Ten Velde, and E. F. M. Wouters, “Massive haemoptysis after
radiotherapy in inoperable non-small cell lung carcinoma: is
endobronchial brachytherapy really a risk factor?”Radiotherapy
& Oncology, vol. 49, no. 2, pp. 175–183, 1998.
[17] M. Reck, F. Barlesi, L. Crino` et al., “Predicting andmanaging the
risk of pulmonary haemorrhage in patientswithNSCLC treated
with bevacizumab: A consensus report from a panel of experts,”
Annals of Oncology, vol. 23, no. 5, pp. 1111–1120, 2012.
[18] M. Q. Baggstrom, M. A. Socinski, X. F. Wang et al., “Mainte-
nance sunitinib following initial platinum-based combination
chemotherapy in advanced-stage IIIB/IV non–small cell lung
cancer: a randomized, double-blind, placebo-controlled phase
III study—CALGB30607 (Alliance),” Journal ofThoracic Oncol-
ogy, vol. 12, no. 5, pp. 843–849, 2017.
[19] G. R. Blumenschein Jr., U. Gatzemeier, F. Fossella et al., “Phase
II, multicenter, uncontrolled trial of single-agent sorafenib in
patients with relapsed or refractory, advanced non-small-cell
lung cancer,” Journal of Clinical Oncology, vol. 27, no. 26, pp.
4274–4280, 2009.
[20] E. C. J. Phernambucq, K. J. Hartemink, E. F. Smit et al.,
“Tumor cavitation in patients with stage iii non-small-cell lung
cancer undergoing concurrent chemoradiotherapy: Incidence
and outcomes,” Journal of Thoracic Oncology, vol. 7, no. 8, pp.
1271–1275, 2012.
[21] M. R. Chaudhuri, “Primary pulmonary cavitating carcinomas,”
Thorax, vol. 28, no. 3, pp. 354–366, 1973.
[22] G. L. Semenza, “Hypoxia-induced factor 1: master regulator of
O2 homeostasis,” Current Opinion in Genetics & Development,
vol. 8, no. 5, pp. 588–594, 1998.
[23] J. L. Bidwell and R. W. Pachner, “Hemoptysis: diagnosis and
management,” American Family Physician, vol. 72, no. 7, pp.
1253–1260, 2005.
[24] A.-M. C. Dingemans, G. Bootsma, A. Van Baardwijk et al., “A
phase i study of concurrent individualized, isotoxic accelerated
radiotherapy and cisplatin-vinorelbine-cetuximab in patients
with stage III non-small-cell lung cancer,” Journal of Thoracic
Oncology, vol. 9, no. 5, pp. 710–716, 2014.
[25] D. B. Landau, L. Hughes, and A. Baker, “IDEAL-CRT: A phase
1/2 trial of isotoxic dose-escalated radiation therapy and con-
current chemotherapy in patients with stage II/III non-small
cell lung cancer,” International Journal of Radiation Oncology,
Biology, Physics, vol. 95, no. 5, pp. 1367–1377, 2016.
[26] K. L. Swanson, C.M. Johnson,U. B. S. Prakash,M.A.McKusick,
J. C. Andrews, and A. W. Stanson, “Bronchial artery emboliza-
tion: experience with 54 patients,” CHEST, vol. 121, no. 3, pp.
789–795, 2002.
[27] M. L. Wong, P. Szkup, and M. J. Hopley, “Percutaneous
embolotherapy for life-threatening hemoptysis,” CHEST, vol.
121, no. 1, pp. 95–102, 2002.
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
